Alliance Pharma Live Discussion

NoQuestionMarks 15 May 2019

Xonvea in the news BBC News Pregnancy sickness: 'I thought I was dying' Hannah is one of 5,000 UK women to share their experience of extreme pregnancy sickness with BBC News.

Gamesinvestor1 27 Mar 2019

Good results hsduk - interesting response, can you highlight what you think is good and what is bad? Games

hsduk101 27 Mar 2019

Good results Id have to say that this has both good and bad points. Id say this is likely to remain flat based on this

Gamesinvestor1 27 Mar 2019

Good results Things are already silly with Brexit, we are not leaving it seems. Fortunately if we have to remain as a weasel vassal state of the EU the economic hit we will take over a very long time will be less seen by companies like APH as it grows it’s world wide (non EU) business to a much bigger proportion of it’s pie. Games

NoQuestionMarks 26 Mar 2019

Good results Not bad, if Nizoral and Xonvea take off we might be off and running to have a run at 100p again. I continue to hold but won’t be adding more unless things get silly with Brexit and we dip back into the 40’s. Good luck all [link]

Gamesinvestor1 26 Mar 2019

Good results [link] LONDON (Alliance News) - Alliance Pharma on Tuesday raised its dividend for 2018 amid a strong revenue performance, though profit fell due to impairments. The pharmaceutical retailer said pretax profit dropped 19% to GBP22.8 million from GBP28.3 million the year before, partly due to a GBP4.3 million impairment of an anti-malarial asset, as the manufacturer ceased supply due to low volumes. There was also a GBP2.5 million impairment and write down of the Synthasia joint venture, after the import licence partner of infant milk formula brand Suprememil notified Alliance the licence would not be renewed. On an underlying basis, however, pretax profit increased by 17% to GBP28.1 million from GBP23.9 million. Revenue for the year grew by 22% to GBP124.0 million from GBP101.6 million due to stronger sales in its International Star brands as well as a contribution from anti-dandruff shampoo Nizoral, acquired from pharmaceutical giant Johnson & Johnson in June. Alliance Pharma said for the first time, sales from outside of the UK outperformed those from within the UK. International sales rose by 59% to GBP41.8 million, Mainland Europe sales grew 25% to GBP25.4 million while sales in the US increased by 10% to GBP4.6 million. Collectively, sales outside of the UK were around GBP71.8 million, while sales in the UK & Ireland declined 5% to GBP52.3 million. Alliance Pharma declared a final dividend of 0.977 pence per share, bringing the total payout to 1.464p, up 10% from 1.221p in 2017. Looking ahead, Alliance Pharma said it made a strong start to 2019, trading in line with expectations for the year. “In 2018 we continued to deliver on our strategy, with strong sales and profit growth, led by our International Star brands and acquisitions. 2018 marked a milestone in the internationalisation of Alliance in that, for the first time, our overseas sales exceeded those in the UK,” said Chief Executive Peter Butterfield. “The acquisition of Nizoral brings increased scale and opportunities for us in the Asia Pacific region and, together with the creation of a trading operation in the US, further increases our international footprint, whilst the UK approval of Xonvea offers further organic growth prospects for the group,” Butterfield added. Shares in Alliance Pharma were up 6.4% at 68.76 pence on Tuesday.

Gamesinvestor1 21 Jan 2019

All good It does seem pretty positive when you consider some of the other announcements of late. I expect the Chairman at GSK left and took a payoff so he could buy some APH lol ! Games - APH is 1.5% of my wad.

NoQuestionMarks 21 Jan 2019

All good Can’t see any negatives here. The integration of the new brands seems to be bearing fruit. More acquisitions are not off the table it would seem. I’d prefer us to concentrate on increasing our free cash flow and getting that debt ratio down to 1 to 1.5 before embarking on another spending spree. I think there will be bargains to be had as Brexit unfolds in the early 2020’s. Continuing to hold and accumulate on weakness. ALLIANCE PHARMA PLC (“Alliance” or the “Group”) Pre-Close Trading Update Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce its unaudited pre-close trading update ahead of the Group’s preliminary results for the year ended 31 December 2018. Revenues on a ‘see-through’ basis* for 2018 were up 22% on the prior year (up 23% on a constant currency basis) at approximately £124.0m (2017: £101.6m, restated following the adoption of IFRS 15). Excluding acquisitions, revenues increased 4% on the prior year (4% on a constant currency basis). Underlying profit before tax is expected to be in line with expectations. Our International Star brands continued to perform strongly in 2018: · Kelo-cote™ delivered an excellent performance, with sales increasing 68% to £22.5m (2017: £13.3m) with stronger than expected growth across the Asia Pacific region and in mainland Europe. · Nizoral™, the medicated anti-dandruff shampoo acquired from Johnson & Johnson (J&J) in June 2018, performed in line with expectations generating ‘see-through’ sales* of £10.9m in the second half of 2018. · MacuShield™ performed well with sales up 6% at £7.0m (2017: £6.6m, restated following the adoption of IFRS 15). · Vamousse™, acquired in December 2017, performed in line with expectations, achieving sales of £5.8m, up 16% on 2017 (under previous ownership), and up 18% on a constant currency basis. · Xonvea™, for the treatment of nausea and vomiting of pregnancy where conservative management has failed, was launched in October 2018 and is on track with expectations, having registered its first sales and formulary inclusions. As expected, revenues from our Local brands returned a better performance in the second half of the year with sales of £40.6m (2017: £37.2m). As a result, sales of Local brands for the year were £77.8m (2017: £81.6m), down 5% on the previous year (down 5% on a constant currency basis). Going forwards, we expect sales in this portfolio to remain broadly stable and in line with the second half 2018 sales on an annualised basis. Free cash flow for the year was slightly stronger than anticipated at approximately £16.1m (2017: £22.0m, restated following the adoption of IFRS 16), after allowing for costs associated with the implementation of the Falsified Medicines Directive, Brexit and launch costs relating to Xonvea. Adjusted net debt/EBITDA leverage was better than expected at approximately 2.33 times (2017: 2.46 times) and, as planned, net debt remained at similar levels to the half year-end at approximately £85.8m (30 June 2018: £86.3m). In 2019, we expect to generate strong free cash flow, which will exceed 2017 levels, and for leverage to reduce to below 2.0 times during the second half of 2019. The Group expects to announce its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019. Peter Butterfield, Chief Executive Officer of Alliance Pharma, commented: “We are very pleased to report continued strong momentum in our business, with sales in 2018 up 22% compared with the previous year. We look forward to delivering further growth in the year ahead and to employing the Group’s strong cashflow to further develop the business as the year progresses.” ‘See-through’ revenues include the underlying sales from Nizoral™. Under the terms of the transitional services agreement with J&J, Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the Asia-Pacific territories transfer from J&J to Alliance, which is expected to occur during 2019 and 2020. Revenues for 2018, on a statutory-reported basis, are expected to be £118.2m, an increase of 16% on the prior year.

NoQuestionMarks 07 Jan 2019

What else do you own? Thanks law doc, Arbuthnot look good, I have only had a quick look thus far but they are on the watchlist and I will give them a good look over. GL.

lawdoc 04 Jan 2019

What else do you own? My focus is on AIM shares which are eligible for IHT such as APH. My latest top-up in late December was Arbuthnot Banking Group (ARBB). I hold many AIM shares but the AIM index took an undeserved bashing (-19%) in 2018. GL.

NoQuestionMarks 31 Dec 2018

What else do you own? I wonder if any of you would mind sharing your investment ideas for the future? Are you holding plenty of cash or have you taken advantage of the pullback? I am only interested in ‘proper’ companies; profit making, dividend paying and without ridiculously high indebtedness. I have gone 50/50; a few companies I have been watching just seemed too cheap and I couldn’t keep my finger from the trigger. In no particular order, I have bought. Strix Group (KETL) 138p. Trading at 10x with a div yield of 3% Woodford Patient Capital Trust (WPCT) 81p. Net asset value of 95p and just promoted to the FTSE250. Lloyds(LLOY) 51p. I have also topped up on APH when we dipped under 65p. I am also watching LPA Group with a view to buying at some point.

NoQuestionMarks 25 Jul 2018

Half year trading update Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2018. The Group traded well in the first half of 2018. Revenues for the period are expected to be 10% higher than the same period last year at approximately £54.5m (H1 2017: £49.4m, restated following the adoption of IFRS 15*); trading profits for the period are expected to increase at a rate lower than sales due largely to the phasing of spend to support marketing and selling activities. On the basis of trading in the year to date, the Board expects revenue and underlying profit before tax for the current financial year to be in line with expectations. Our International Star brands continued to deliver a strong performance in the first half. Sales of Kelo-Cote® increased 77% to £10.9m (H1 2017: £6.2m). MacuShield® also performed well with sales up 22% at £3.7m (H1 2017: £3.0m, restated*). Vamousse®, a range of products for the prevention and treatment of head lice, acquired in December 2017, performed in line with expectations. Vamousse achieved sales of £2.7m in the period and is well-placed to grow in the second half, which includes the important ‘back-to-school’ period in the US and UK. Elsewhere in the portfolio, our local hero brands performed in line with expectations and the bedrock slightly behind expectations, due to a combination of manufacturing delays and distributor order phasing. Revenues were adversely impacted by currency movements in the period by approximately £0.9m, due mainly to the strengthening of Sterling, primarily against the US Dollar. On a constant currency basis, sales would have increased by 12% and, excluding acquisitions, sales would have increased 4%. The effect of currency on operating profits will be smaller due to the reductions in cost of goods and the hedging impact of operating costs denominated in these currencies. Underlying free cash flow in the first half of 2018 is expected to be approximately £10.1m (H1 2017: £11.1m). The reduction on the prior year is driven by a planned increase in total inventory holding of £2.1m, following the acquisition of Vamousse and Ametop™ at the end of 2017, and the timing of certain tax payments in the period. Net debt increased by approximately £14.0m to £86.3m as at 30 June 2018 (31 December 2017: £72.3m), due to additional debt drawn of £28.0m to fund the acquisition (completed on 21 June 2018) of Nizoral™, a medicated anti-dandruff shampoo, for the Asia-Pacific markets. This additional debt is partially offset by the Group’s underlying cash generation in the period, a £2.4m cash receipt following the disposal of the Group’s interest in Unigreg Limited announced in April 2018 and the final £1.0m compensation received from Sinclair Pharma plc. Leverage (defined as adjusted net debt/proforma EBITDA) reduced to approximately 2.4 times at 30 June 2018 (31 December 2017: 2.5 times). We expect leverage to modestly reduce in the second half, with the cash generated from the underlying business more than offsetting the pre-marketing/launch activities of Xonvea®, a prescription product for the treatment of nausea and vomiting of pregnancy that was approved by the MHRA on 6 July 2018, and the expected increase in working capital following the Nizoral acquisition. We expect to launch Xonvea in the UK in the Autumn of this year. Furthermore, we will commence the regulatory approval process for a further nine European countries for which we have in-licensed the marketing rights. Whilst we do not expect to generate significant sales of Xonvea in the UK until H2 2019, and later for the European markets, the product has the potential to be a substantial growth driver for Alliance. The Group expects to announce its interim results for the six months ended 30 June 2018 on 19 September 2018. The adoption of IFRS 15 ‘Revenue from Contracts with Customers’ has resulted in the reclassification of certain rebates as a deduction from Revenue; previously these rebates were included within Cost of Sales. To ensure comparability, the H1 2017 comparatives have been restated on the same basis, resulting in a reduction in sales

Gamesinvestor1 25 Jul 2018

Trading Statement [link] Added to my holding on the dip this morning :- “”“The Group traded well in the first half of 2018. Revenues for the period are expected to be 10% higher than the same period last year at approximately £54.5m (H1 2017: £49.4m, restated following the adoption of IFRS 15*); trading profits for the period are expected to increase at a rate lower than sales due largely to the phasing of spend to support marketing and selling activities. On the basis of trading in the year to date, the Board expects revenue and underlying profit before tax for the current financial year to be in line with expectations.”" Games

fundfemale 08 Jun 2018

Target price Numis new target price 99p.Very conservative if pregnancy sickness drug gains approval.

fundfemale 07 Jun 2018

Diclectin sales value The analyst at Numis had peak sales at 20 million GBP.That would lift current sales turnover by approx. 20%.Its great news. BTW Ex dividend 14.06.2018